0.06
-0.0034(-5.81%)
Currency In USD
| Previous Close | 0.06 |
| Open | 0.06 |
| Day High | 0.06 |
| Day Low | 0.06 |
| 52-Week High | 1.33 |
| 52-Week Low | 0.05 |
| Volume | 18.72M |
| Average Volume | 28.73M |
| Market Cap | 14.23M |
| PE | -0.08 |
| EPS | -0.66 |
| Moving Average 50 Days | 0.19 |
| Moving Average 200 Days | 0.41 |
| Change | -0 |
If you invested $1000 in Adaptimmune Therapeutics plc (ADAP) 10 years ago, it would be worth $4.96 as of August 22, 2025 at a share price of $0.055. Whereas If you bought $1000 worth of Adaptimmune Therapeutics plc (ADAP) shares 5 years ago, it would be worth $6.61 as of August 22, 2025 at a share price of $0.055.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Newsfile
Jul 28, 2025 11:30 AM GMT
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price is $55m in cash to be paid upon consummation
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Newsfile
May 07, 2025 4:00 PM GMT
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provid
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Newsfile
Mar 20, 2025 11:00 AM GMT
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate r